Signum Biosciences Names Braham Shroot as Chief Executive Officer

Experienced pharmaceutical executive leads innovative biotech company

PRINCETON, New Jersey, August 5, 2010 - Signum Biosciences, Inc. today announced the appointment of Dr. Braham
Shroot, formerly CSO of Barrier Therapeutics, as Chief Executive Officer. Dr.
Shroot replaces Dr. Gregory Stock who will continue to remain active with the
Company as a member of the board.

"Braham Shroot brings to Signum an outstanding track record of success in
growing value at both start-up and major pharmaceutical companies including
Barrier Therapeutics, DFB Bioscience, and Galderma," said Maxwell Stock,
President of Signum Biosciences. "We welcome him to the Signum team and look
forward to seeing the company progress under his leadership."

"This is a very exciting time for Signum, with the commercialization of
the company's first skin-care compound, Arazine(TM), by its partner, Rohto
Pharmaceutical in Japan," said Dr. Shroot. "I am equally enthusiastic about
Signum's innovative pipeline which holds significant potential to help
patients with difficult-to-treat chronic inflammatory and age related
pathologies."

Braham Shroot Biography

Braham Shroot is the former CSO of Barrier Therapeutics, Inc., a public
dermatology-focused pharmaceutical company, which was acquired by Stiefel
Laboratories Inc., in August 2008. Prior to Barrier, Dr. Shroot was CSO and
Vice President of R&D for DFB Pharmaceuticals, Inc., a fully integrated
private specialty pharmaceutical company with a focus on skin, wound care,
and surgical markets. Before DFB, Dr. Shroot was at L'Oreal where he was
Group Leader and eventually Vice General Manager of the newly created
Galderma entity which he helped to establish. Dr. Shroot earned his B.Sc. in
Chemistry and Ph.D. in Organic Chemistry at Glasgow University, Scotland, UK.
He is also a board member of the Wound Healing Society, and associate Editor
of the Journal of Investigative Dermatology.

About Signum Biosciences

Signum Biosciences is a private biotechnology company dedicated to
developing small-molecule therapeutics derived from its Signal Transduction
Modulation (STM) platform to modulate signal transduction imbalances. Through
research on protein networks that control biological systems, Signum is
developing therapeutic candidates for inflammatory and neurodegenerative
diseases. Signum's STM technology provides many opportunities for the
development of novel consumer products and pharmaceutical candidates.

For more information please visit the Signum website:
www.signumbiosciences.com

Alex Monteith, +1-732-329-6344, ext. 204, amonteith at signumbio.com